Evidence map›Paper›PMID 25835492›Full record

Trial reportPloS one2015

No impact of vitamin D on the CYP3A biomarker 4β-hydroxycholesterol in patients with abnormal glucose regulation.

Buster Mannheimer, Henrik Wagner, Claes-Göran Östenson, Ulf Diczfalusy

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01497132 (Effects of Vitamin D on Beta Cell Function and Insulin Sensitivity in Pre-diabetes and Diabetes Mellitus Type 2 - EVIDENS), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01497132 phase4completednot on this map

Effects of Vitamin D on Beta Cell Function and Insulin Sensitivity in Pre-diabetes and Diabetes Mellitus Type 2 - EVIDENS

TypeinterventionalSponsorKarolinska InstitutetRan2012 to 2013Enrolled44ConditionsDiabetes Mellitus, Type 2, Glucose Intolerance, Vitamin D DeficiencyArmsVitamin D3, Placebo
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Role of vitamin D receptor in the regulation ofActa pharmaceutica Sinica. B · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Buster MannheimerKarolinska Institutet, Department of Clinical Science and Education at Södersjukhuset, SE 118 82, Stockholm, Sweden.
Henrik WagnerKarolinska Institutet, Department of Molecular Medicine and Surgery, D2:04, SE 171 76, Stockholm, Sweden.
Claes-Göran ÖstensonDepartment of Endocrinology, Metabolism and Diabetes at Karolinska Institutet, Karolinska University Hospital, D2:04, SE 171 76, Stockholm, Sweden.
Ulf DiczfalusyDepartment of Laboratory Medicine, Division of Clinical Chemistry at Karolinska Institutet, Karolinska University Hospital, C1.74, Huddinge, SE-141 86, Stockholm, Sweden.
Karolinska Institutet · SEKarolinska University Hospital · SEStockholm South General Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate the effect of vitamin D3 on hepatic Cytochrome P450 enzyme (CYP) 3A4 in patients with abnormal glucose regulation using the endogenous marker 4β-hydroxycholesterol (4β-OHC):cholesterol ratio.

methodsThe present study took advantage of a trial primarily aiming to investigate the effect of vitamin D3 on beta cell function and insulin sensitivity in patients with abnormal glucose regulation. 44 subjects were randomized to receive vitamin D3, 30000 IU given orally once weekly or placebo for 8 weeks. The two sample t-test was used to test the means of the intra-individual differences of 4β-OHC:cholesterol ratio between the two groups.

resultsMean (SD) 4β-OHC in the whole group of patients before and after the intervention was 26 (11) ng/ml and 26 (12). Mean (SD) 4β-OHC:cholesterol ratio in the whole group of patients before and after the intervention was 0.12 (0.046) and 0.13 (0.047). In the Vitamin D group mean (SD) serum 25-OH-vitamin D3 increased from 46 (16) to 85nM (13) during the corresponding time period. To investigate the impact of vitamin D3 on hepatic CYP3A4 we calculated the mean intra-individual differences in 4β-OHC:cholesterol ratio (delta 4β-OHC:cholesterol ratio) before versus after the intervention in the two treatment groups. The difference (95% CI) between delta 4β-OHC:cholesterol ratio in the control group and intervention group was -0.0010 (-0.0093, 0.0072), a difference being not statistically significant (p = 0.80).

conclusionsWe provide further evidence that vitamin D3 may not substantially affect hepatic CYP3A4. This does not exclude the possibility of an impact of intestinal first-pass metabolism of orally administered drugs which should be investigated.

trial registrationClinicalTrials.gov NCT01497132.

Indexed as

AgedBiomarkersBlood GlucoseBody Mass IndexCholesterolCytochrome P-450 CYP3ADiabetes MellitusDouble-Blind MethodFastingFemaleGene ExpressionGlucose Tolerance TestHumansHydroxycholesterolsInsulin ResistanceLiverBiomarkersBlood Glucosecholest-5-ene-3,4-diolCholesterolCYP3A4 protein, humanCytochrome P-450 CYP3AHydroxycholesterolsVitamin D

Identifiers

PMID25835492
PMCPMC4383380
OpenAlexW2089313075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.